Pilot Program To Evaluate Proposed Proprietary Name Submissions; Procedures To Register for Participation and Submit Data, 50806-50809 [E9-23620]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 74, Number 189 (Thursday, October 1, 2009)]
[Notices]
[Pages 50806-50809]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23620]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0281]


Pilot Program To Evaluate Proposed Proprietary Name Submissions; 
Procedures To Register for Participation and Submit Data

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
opportunity for pharmaceutical firms (applicants) to participate in a 
voluntary 2-year pilot program for the evaluation of proposed 
proprietary names to be conducted by FDA's Center for Drug Evaluation 
and Research (CDER) and Center for Biologics Evaluation and Research 
(CBER). The pilot program will enable participating pharmaceutical 
firms to evaluate proposed proprietary names and submit the data 
generated from those evaluations to FDA for review, as outlined in the 
FDA concept paper entitled ``PDUFA Pilot Project Proprietary Name 
Review.'' This document describes procedures to register and submit 
data for applicants who wish to have their proposed proprietary names 
evaluated under the pilot program.

DATES: FDA will begin accepting requests to register for the voluntary 
pilot program on October 1, 2009.

ADDRESSES: Submit written requests for single copies of the concept 
paper to the Division of Drug Information, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002, or the Office of 
Communication, Outreach and Development (HFM-40), Center for Biologics 
Evaluation and Research (CBER), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852-1448. The concept paper may also be 
obtained by mail by calling CBER at 1-800-835-4709 or 301-827-1800. 
Send two self-addressed adhesive labels to assist the office in 
processing your requests. Requests should be identified with the docket 
number found in brackets in the heading of this document. See the 
SUPPLEMENTARY

[[Page 50807]]

INFORMATION section for electronic access to the concept paper.

FOR FURTHER INFORMATION CONTACT:
    Carol Holquist, Center for Drug Evaluation and Research, Office of 
Surveillance and Epidemiology, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 22, rm. 4416, Silver Spring, MD 20993-0002, e-
mail: proprietarynamereview@fda.hhs.gov with the subject line 
identified as ``PNR Pilot Program for CDER/DMEPA;'' or
    Ele Ibarra-Pratt, Center for Biologics Evaluation and Research, 
Advertising and Promotional Labeling Branch (HFM-602), Food and Drug 
Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-
1448, e-mail: CBERAPLB@fda.hhs.gov with the subject line identified as 
``PNR Pilot Program for CBER/APLB.''

SUPPLEMENTARY INFORMATION:

I. Background

    In title I of the Food and Drug Administration Amendments Act of 
2007 (FDAAA) (Public Law 110-85), Congress reauthorized and expanded 
the Prescription Drug User Fee program for fiscal years 2008 to 2012 
(PDUFA IV). In performance goals agreed to in conjunction with the 
reauthorization of PDUFA IV, FDA agreed to publish a concept paper on 
and implement a pilot program to enable pharmaceutical firms 
participating in the pilot program to evaluate proposed proprietary 
names and submit the data generated from those evaluations to FDA for 
review. (See section IX.B at https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119243.htm.) This process is consistent with 
other areas of drug review in which FDA evaluates data generated by 
firms rather than producing such data independently. FDA agreed to 
conduct a public meeting to discuss the content of the concept paper, 
which describes the following: (1) The logistics of the pilot program, 
(2) proposed recommendations for carrying out a proprietary name 
review, and (3) the way FDA intends to review submissions made under 
the pilot program. In keeping with the performance goals:
     On June 5 and 6, 2008, FDA held a public technical meeting 
(see meeting notice at 73 FR 27001, May 12, 2008), to discuss a draft 
concept paper describing the pilot program and FDA's thinking about how 
pharmaceutical firms could participate in the pilot program to evaluate 
proposed proprietary names and submit the data generated to FDA for 
review. FDA considered comments received at the meeting and submitted 
to the public docket.
     In the Federal Register of October 7, 2008 (73 FR 58604), 
FDA announced the availability of the concept paper entitled ``PDUFA 
Pilot Project Proprietary Name Review.'' The concept paper provides 
information to pharmaceutical firms about how to evaluate proposed 
proprietary names at the new drug application (NDA) or biologics 
license application (BLA) phase or investigational new drug application 
(IND) phase (before NDA or BLA submission) or when an abbreviated new 
drug application (ANDA) is submitted, and to submit the data generated 
from those evaluations to FDA for review.
    In addition to developing the concept paper for the pilot program, 
FDA announced the availability of a draft guidance for industry 
entitled ``Contents of a Complete Submission for the Evaluation of 
Proprietary Names'' (draft proprietary names submission guidance) (73 
FR 71009, November 24, 2008).\1\ FDA also announced the availability of 
the source code and supporting technical documentation for the Phonetic 
Orthographic Computer Analysis (POCA) software program, an analytic 
tool designed to help identify drug and biologic names and medical 
terminology that are phonetically and orthographically similar to one 
another (74 FR 7450, February 17, 2009). POCA is one analytic tool that 
FDA uses to review proposed proprietary drug and biologic names.
---------------------------------------------------------------------------

    \1\ The draft proprietary names submission guidance is not 
intended to address the PDUFA IV performance goal of developing and 
implementing a pilot program for evaluating proposed proprietary 
names, or other PDUFA IV performance goals. Rather, the draft 
proprietary names submission guidance, when finalized, is intended 
to promote prevention of medication errors by assisting industry in 
the submission of complete product information that will help FDA to 
evaluate the safety of proposed proprietary drug and biological 
product names, taking into account other factors that, in 
association with the name, can contribute to medication errors. 
Persons with access to the Internet may obtain the draft proprietary 
names submission guidance at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, 
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, or 
https://www.regulations.gov.
---------------------------------------------------------------------------

II. PDUFA Pilot Program Proprietary Name Review Logistics

A. Overview

    As discussed in the concept paper (section III of PDUFA Pilot 
Program--Logistics), applicants should contact the appropriate FDA 
center to register to participate in the pilot program before making 
their proprietary name submissions (see FOR FURTHER INFORMATION CONTACT 
and DATES). This document describes the following procedures for 
implementing the pilot program:
     Who the FDA points-of-contact are to register for 
participation,
     How to register by e-mail and what information to provide,
     When and where to send proposed proprietary name 
submissions, and
     What type of information to include in a complete 
submission to support parallel reviews of a proposed proprietary name.

B. Registration Is Required To Participate in the Pilot Program

    As discussed in the concept paper, FDA will strive to include a 
cross-section of applicants that represent large, medium, and small 
companies during the 2-year program. FDA hopes that 25 to 50 proposed 
proprietary name submissions will be received and reviewed under the 
pilot program. To achieve this goal and to manage workload within the 
PDUFA IV timelines, FDA will only be able to accept an average of one 
to two submissions per month. Consequently, it will be necessary to 
register to participate before making a proposed proprietary name 
submission under the pilot program. To determine if space is available 
for an applicant to participate in the pilot program and agree on a 
date to make its planned submission, applicants should contact the 
designated point-of-contact for the appropriate center by e-mail as 
described in the following two sections of this document.
1. Registration for CDER Review
    For proposed proprietary names that are being submitted as part of 
an IND, NDA, BLA, ANDA, or supplement reviewed by CDER, contact Carol 
Holquist by e-mail at proprietarynamereview@fda.hhs.gov. Applicants 
should provide the following information in the e-mail for 
registration:
     E-mail subject heading: ``PNR Pilot Program for CDER/
DMEPA,''
     First sentence in e-mail should indicate: ``Request for 
Registration in PNR Pilot Program,''
     Company name,
     Name of U.S. regulatory contact (include telephone number 
and e-mail address),
     Name of entity conducting proprietary name analysis 
(applicant company or third-party vendor),
     Application type (IND, NDA, BLA, ANDA, or supplement) and 
application number,

[[Page 50808]]

     Proposed proprietary name (identify primary and alternate 
proprietary name, if any), and
     Approximate (requested) month for intended submission.
2. Registration for CBER Review
    For biological drug products that are the subject of an IND, NDA, 
BLA, or supplement reviewed by CBER, contact Ele Ibarra-Pratt by e-mail 
at CBERAPLB@fda.hhs.gov. Applicants should provide the same information 
listed previously in section II.B.1 of this document, except that the 
e-mail subject heading should be: ``PNR Pilot Program for CBER/APLB.''

C. FDA Will Confirm Registration

    FDA will respond to an applicant's e-mail request for registration 
to participate in the voluntary pilot program. The FDA point-of-contact 
will determine if the requested date of submission, by month, is 
available. If the requested date is available, FDA will e-mail the 
applicant confirming the applicant's registration in the pilot program.
    If the applicant's requested date of submission, by month, is not 
available, FDA will propose an alternate date for the applicant to make 
the proprietary name submission under the pilot program. FDA will 
confirm the applicant's registration to participate once the applicant 
replies to FDA's e-mail acknowledging the acceptability of the 
alternate date.
    If the alternate date is not acceptable to the applicant, the 
applicant should promptly notify FDA by e-mail. If an alternate date 
cannot be agreed upon and/or the applicant does not wish to participate 
in the pilot program, the applicant should so state in the e-mail 
response to FDA. An applicant that is not registered in the pilot 
program will submit its proposed name to the FDA for analysis and 
evaluation using FDA's traditional approach to the review of proposed 
proprietary names (see the draft proprietary names submission 
guidance).

D. Submissions Under the Pilot Program

1. When To Submit
    Applicants registered in the pilot program should send their 
submissions to FDA for receipt within the first 2 business days of the 
agreed month. If the submission is not received on the first 2 business 
days of the agreed month, workload priorities may affect FDA's ability 
to review the proposed proprietary name as scheduled under the pilot 
program and FDA may convert the submission to a traditional review.
2. What to Submit--Content of Submission for Parallel Reviews
    For all proprietary name submissions, the first page of the 
submission should include the statement ``REQUEST FOR PROPRIETARY NAME 
REVIEW'' in bold, capital letters. This statement should be immediately 
followed by the header ``PILOT PROGRAM'' in bold, capital letters.
    Applicants should separate the data contained in the single 
submission into two separate sections to enable parallel reviews by FDA 
as follows:
     Section I should be labeled ``TRADITIONAL REVIEW'' and 
should contain the proposed proprietary name information that is 
submitted under FDA's traditional practice. For more information, see 
the draft proprietary names submission guidance and section III of 
Appendix B (Proposed Template for a Pilot Program Submission) of the 
concept paper. If this information is submitted as part of the pilot 
program, it is not necessary to submit it to the agency again.
     Section II should be labeled ``PILOT REVIEW'' and should 
contain the comprehensive evaluation of the proposed proprietary name, 
including the information and data listed in Appendix B of the concept 
paper. Only the data for the applicant's primary proposed proprietary 
name should be submitted. If the applicant has identified an alternate 
proprietary name, requests for the data regarding that name will be 
made only if FDA decides that the primary proposed proprietary name is 
not acceptable, after the decision is communicated to the applicant 
(see section II.E.1 of this document, Process to Request FDA Review of 
an Alternate Proposed Proprietary Name).
    Although Sections I and II are contained in a single submission, 
the applicant should ensure that the data contained in each section can 
be reviewed independently. Data should not be cross-referenced; each 
section should encompass all of the data elements required for a 
complete submission. The prominent identification of the two sections 
of proposed proprietary name information will maintain the validity of 
the independent parallel reviews.
    All proprietary name submissions under the pilot program will be 
screened for completeness (i.e., submission of information needed to 
evaluate the proprietary name). Applicants will be notified in writing 
if the submission does not contain all of the information needed to 
conduct the parallel reviews. Once the proposed proprietary name 
submission is considered complete, the submission will be reviewed 
within the PDUFA IV review performance goal timeframes \2\ (i.e., IND--
180 days from receipt of complete submission; NDA or BLA--90 days from 
receipt of complete submission).
---------------------------------------------------------------------------

    \2\ For proposed proprietary names that are submitted in an 
ANDA, the PDUFA IV performance goal timeframes do not apply.
---------------------------------------------------------------------------

3. How To Submit--Paper or Electronic Form
    Submissions may be in paper or electronic form. For paper 
submissions, applicants should submit three copies of the submission to 
the same address as the original product application with which the 
proposed proprietary name is associated. Submit packages for proposed 
proprietary names for drugs, including biologics, that are the subject 
of an IND, NDA, BLA, or supplement to be reviewed by CDER to:
    Center for Drug Evaluation and Research,
    Food and Drug Administration,
    Documents and Records Section,
    5901-B Ammendale Road,
    Beltsville, MD 20705-1266.
    Submit packages for proposed proprietary names for biological drug 
products that are the subject of an IND, NDA, BLA, or supplement to be 
reviewed by CBER to:
    Center for Biologics Evaluation and Research,
    Document Control Center (HFM-602),
    1401 Rockville Pike, rm. 200N,
    Rockville, MD 20852-1448.
    For electronic submissions, applicants should refer to FDA's Web 
site ``Electronic Common Technical Document (eCTD)'' at https://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm153574.htm and at 
https://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/ucm163685.htm. Refer specifically to the following documents on the Web 
page:
     Guidance for industry on ``Providing Regulatory 
Submissions in Electronic Format--Human Pharmaceutical Product 
Applications and Related Submissions Using the eCTD Specifications,''
     eCTD Backbone File Specifications for Module 1, and
     FDA eCTD Table of Contents Headings and Hierarchy.
    Applicants are encouraged to use the Electronic Submissions Gateway 
(ESG) to submit regulatory information. For information on the use of 
the ESG, refer

[[Page 50809]]

to https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/default.htm.
4. Communications Concerning the Planned Submission
    Applicants participating in the pilot program should contact the 
appropriate center point-of-contact by e-mail (see FOR FURTHER 
INFORMATION CONTACT) 120 days prior to the intended date of the 
proposed proprietary name submission to discuss specific details of the 
planned submission. If applicants plan to use alternative or additional 
methods to evaluate the safety of their proposed proprietary name(s), 
they should inform the appropriate center 120 days prior to their 
planned submission date. FDA does not have the resources to review the 
proposed alternative methodologies with the intent of coming to 
agreement with an applicant on the appropriateness of these alternative 
methodologies prior to submission. In such cases, FDA will review the 
alternative methodologies during the review of the actual submission.
    If applicants have questions concerning the planned submission 
under the pilot program, they should contact the appropriate center 
point-of-contact by e-mail (see FOR FURTHER INFORMATION CONTACT) to 
discuss their questions. If necessary, applicants will be asked to 
submit their questions in writing; in some cases, a teleconference or 
face-to-face meeting to discuss the planned submission may be 
appropriate.

E. Process To Request FDA Review of an Alternate Proposed Proprietary 
Name

    If, after parallel reviews of the proprietary name submission, FDA 
informs the applicant that the primary proposed proprietary name is 
unacceptable, the applicant should confirm in writing that it would 
like its previously identified alternate proposed proprietary name to 
be reviewed or submit a different alternate proprietary name. At this 
time, the applicant can request to have the alternate proprietary name 
evaluated by FDA under the pilot program or by the traditional review 
method. If the request is to have the alternate proprietary name 
reviewed under the pilot program, the applicant should submit the 
comprehensive evaluation of the alternate proposed proprietary name, 
including the information and data described in section II.D.2 of this 
document. If the request is to have the alternate proprietary name 
evaluated by the traditional method, the applicant may reference the 
information previously submitted for parallel review of the proposed 
primary proprietary name (Section I of the pilot program submission 
labeled ``TRADITIONAL REVIEW'').
    A new proprietary name review clock for an alternate proposed 
proprietary name will not start until:
    (1) The applicant has confirmed to the appropriate center, in 
writing, that it would like its alternate proprietary name evaluated by 
traditional review method or
    (2) FDA receives the applicant's submission of an alternate 
proposed proprietary name along with the comprehensive information for 
section II ``PILOT REVIEW'' described in section II.D.2 of this 
document.
    For either review method requested (traditional or pilot), the same 
PDUFA IV review performance goal timeframes apply to the review of the 
submission of an alternate proposed proprietary name (i.e., IND--180 
days from receipt of complete submission; NDA or BLA--90 days from 
receipt of complete submission).
    If the applicant requests that its alternate proprietary name be 
evaluated under the pilot program, the agency will take into account 
the date of the alternate proprietary name submission as it relates to 
the PDUFA IV goal for the application. The responsible center will use 
discretion to determine whether the agency will conduct a parallel 
review of the applicant's analysis or only a proprietary name 
evaluation using FDA's traditional approach. Although FDA would ideally 
also review the applicant's completed proprietary name analysis for the 
alternate name under the pilot program, resources may not permit such a 
review. Factors such as staffing will be used in making this 
determination.

F. Duration and Evaluation of the Pilot Program

    At the end of fiscal year 2011, or after accruing 2 years of 
experience with pilot program submissions, FDA intends to evaluate the 
pilot program to determine whether to have applicants perform their own 
proprietary name analysis and submit resulting data to FDA for review. 
The results of this pilot program and recommended additions and/or 
changes to methods based on the reported results will be discussed in a 
future public meeting. Following that meeting, FDA will publish a draft 
guidance describing the best test methods for proprietary name 
evaluation.

III. Paperwork Reduction Act of 1995

    The information collection provisions of this pilot program, 
excluding the submission of information that is part of the agency's 
traditional review of proprietary names, have been submitted to the 
Office of Management and Budget (OMB) for review, as required by 
section 3507 of the Paperwork Reduction Act of 1995. The provisions 
were approved and assigned OMB control number 0910-0648. This approval 
expires September 30, 2012. The proprietary name information submitted 
as part of the traditional review of proprietary names is approved 
under OMB control numbers 0910-0001 and 0910-0338. An agency may not 
conduct or sponsor, and a person is not required to respond to, a 
collection of information unless it displays a currently valid OMB 
control number.

IV. Electronic Access

    Persons with access to the Internet may obtain the concept paper at 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072229.pdf.

    Dated: September 25, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-23620 Filed 9-30-09; 8:45 am]
BILLING CODE 4160-01-S